{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:40:04Z","timestamp":1751031604152,"version":"3.41.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Heart failure with preserved ejection fraction (HFpEF) presents as a growing challenge, accounting for nearly half of all heart failure diagnoses. It is characterized as a clinical condition with normal ejection fraction but impaired diastolic function leading to reduced exercise capacity, frequent hospitalization, and increased mortality, especially in the elderly population with multiple comorbidities like atrial fibrillation, hypertension, and coronary artery disease. Beta-blockers (BBs) have historically been a primary therapy in patients with heart failure reduced ejection fraction due to their proven benefits on mortality and hospitalizations. Although BBs have been utilized in HFpEF for the management of comorbidities, their role in HFpEF remains uncertain and controversial. Clinicians have used BBs for targeted management of atrial fibrillation and ischemic heart disease. However, emerging research highlights the risks of BB-mediated amplification of chronotropic incompetence, reduction in cardiac output during exertion, and worsening symptoms in certain HFpEF phenotypes with low output, such as cardiac amyloidosis. These findings add to the already existing ambiguity from limited randomized trials and mixed results from observational studies and meta-analyses. This narrative review aims to synthesize the current data regarding BB use in HFpEF and explore their mechanistic rationale. Additionally, we seek to clarify the clinical indications and potential harms. Future research, including targeted trials, is still needed to further define the appropriate use of BBs in the population.<\/jats:p>","DOI":"10.1097\/crd.0000000000000987","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:00:41Z","timestamp":1751029241000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Beta-Blockers in Heart Failure With Preserved Ejection Fraction: A Declining Role in Contemporary Management"],"prefix":"10.1097","author":[{"given":"Nathaniel","family":"Abittan","sequence":"first","affiliation":[{"name":"Cardiology and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Cheikhali","sequence":"additional","affiliation":[{"name":"Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasser","family":"Radwan","sequence":"additional","affiliation":[{"name":"Cardiology and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia H.","family":"Ostrow","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Cardiology and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg M.","family":"Lanier","sequence":"additional","affiliation":[{"name":"Cardiology and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"R1-20250627","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R2-20250627","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R3-20250627","doi-asserted-by":"crossref","first-page":"102015","DOI":"10.1016\/j.cpcardiol.2023.102015","article-title":"Revisiting beta-blocker therapy in heart failure with preserved ejection fraction.","volume":"48","author":"Kaddoura","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"R4-20250627","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jchf.2023.05.023","article-title":"Should beta-blockers be used in heart failure if the LVEF is not reduced?","volume":"11","author":"Heidenreich","year":"2023","journal-title":"JACC Heart Fail"},{"key":"R5-20250627","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"R6-20250627","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jchf.2023.09.007","article-title":"Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial.","volume":"12","author":"Peikert","year":"2024","journal-title":"JACC Heart Fail"},{"key":"R7-20250627","doi-asserted-by":"crossref","first-page":"102376","DOI":"10.1016\/j.cpcardiol.2024.102376","article-title":"Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): a systematic review and meta-analysis.","volume":"49","author":"Kaddoura","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"8_Part_1","key":"R8-20250627","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction.","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"R9-20250627","doi-asserted-by":"crossref","first-page":"e1916598","DOI":"10.1001\/jamanetworkopen.2019.16598","article-title":"Association of \u03b2-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial.","volume":"2","author":"Silverman","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R10-20250627","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial.","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet (London, England)"},{"key":"R11-20250627","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction.","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"R12-20250627","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"R13-20250627","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.2013.905","article-title":"Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.","volume":"309","author":"Edelmann","year":"2013","journal-title":"JAMA"},{"key":"R14-20250627","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"R15-20250627","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa032566","article-title":"Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle.","volume":"350","author":"Zile","year":"2004","journal-title":"N Engl J Med"},{"key":"R16-20250627","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1161\/CIRCULATIONAHA.107.716886","article-title":"Role of left ventricular stiffness in heart failure with normal ejection fraction.","volume":"117","author":"Westermann","year":"2008","journal-title":"Circulation"},{"key":"R17-20250627","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/eurheartj\/ehq426","article-title":"Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment.","volume":"32","author":"Borlaug","year":"2011","journal-title":"Eur Heart J"},{"key":"R18-20250627","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.105.573865","article-title":"Matrix metalloproteinases\/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.","volume":"113","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"R19-20250627","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1161\/CIRCULATIONAHA.104.516963","article-title":"Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.","volume":"112","author":"Heymans","year":"2005","journal-title":"Circulation"},{"key":"R20-20250627","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/HYPERTENSIONAHA.109.149112","article-title":"Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction.","volume":"55","author":"Gonz\u00e1lez","year":"2010","journal-title":"Hypertension"},{"key":"R21-20250627","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1161\/01.CIR.102.16.1944","article-title":"A matrix metalloproteinase induction\/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.","volume":"102","author":"Spinale","year":"2000","journal-title":"Circulation"},{"key":"R22-20250627","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure.","volume":"111","author":"Borb\u00e9ly","year":"2005","journal-title":"Circulation"},{"key":"R23-20250627","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"R24-20250627","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1161\/CIRCULATIONAHA.114.009625","article-title":"Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.","volume":"131","author":"Mohammed","year":"2015","journal-title":"Circulation"},{"key":"R25-20250627","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s12471-016-0810-1","article-title":"Understanding heart failure with preserved ejection fraction: where are we today?","volume":"24","author":"van Heerebeek","year":"2016","journal-title":"Neth Heart J"},{"key":"R26-20250627","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1253\/circj.CJ-12-0664","article-title":"Cyclic GMP-dependent signaling in cardiac myocytes.","volume":"76","author":"Takimoto","year":"2012","journal-title":"Circ J"},{"key":"R27-20250627","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jacc.2009.05.012","article-title":"Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.","volume":"54","author":"Phan","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R28-20250627","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2010.03.077","article-title":"Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.","volume":"56","author":"Borlaug","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250627","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardfail.2008.02.012","article-title":"Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest.","volume":"14","author":"Ennezat","year":"2008","journal-title":"J Card Fail"},{"key":"R30-20250627","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction.","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"key":"R31-20250627","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jacc.2009.05.013","article-title":"Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction.","volume":"54","author":"Borlaug","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R32-20250627","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1161\/01.CIR.0000048123.22359.A0","article-title":"Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations.","volume":"107","author":"Kawaguchi","year":"2003","journal-title":"Circulation"},{"key":"R33-20250627","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0735-1097(01)01447-4","article-title":"Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance.","volume":"38","author":"Hundley","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R34-20250627","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jacc.2007.07.032","article-title":"Impact of arterial load and loading sequence on left ventricular tissue velocities in humans.","volume":"50","author":"Borlaug","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R35-20250627","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1161\/CIRCULATIONAHA.108.838698","article-title":"Age-associated increases in pulmonary artery systolic pressure in the general population.","volume":"119","author":"Lam","year":"2009","journal-title":"Circulation"},{"key":"R36-20250627","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jjcc.2013.10.014","article-title":"Relation of risk factors with response to carvedilol in heart failure with preserved ejection fraction \u2013 A report from the Japanese Diastolic Heart Failure Study (J-DHF).","volume":"63","author":"Yamamoto","year":"2014","journal-title":"J Cardiol"},{"key":"R37-20250627","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejheart.2004.02.003","article-title":"Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC).","volume":"6","author":"Bergstr\u00f6m","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"R38-20250627","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.amjcard.2007.08.050","article-title":"Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or=65 years of age with heart failure and preserved left ventricular systolic function.","volume":"101","author":"Shah","year":"2008","journal-title":"Am J Cardiol"},{"key":"R39-20250627","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"R40-20250627","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.2014.15241","article-title":"Association between use of \u03b2-blockers and outcomes in patients with heart failure and preserved ejection fraction.","volume":"312","author":"Lund","year":"2014","journal-title":"JAMA"},{"key":"R41-20250627","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","article-title":"Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials.","volume":"39","author":"Cleland","year":"2018","journal-title":"Eur Heart J"},{"key":"R42-20250627","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/heartjnl-2017-311652","article-title":"Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","volume":"104","author":"Zheng","year":"2018","journal-title":"Heart"},{"key":"R43-20250627","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjmed.2018.07.008","article-title":"Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate.","volume":"131","author":"Lam","year":"2018","journal-title":"Am J Med"},{"key":"R44-20250627","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2020.23138","article-title":"Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life: the RATE-AF randomized clinical trial.","volume":"324","author":"Kotecha","year":"2020","journal-title":"JAMA"},{"key":"R45-20250627","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of \u03b2-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction.","volume":"78","author":"Palau","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R46-20250627","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"R47-20250627","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00392-024-02451-0","article-title":"Beta blockers are associated with lower all-cause mortality among HFpEF patients.","volume":"113","author":"Ibrahim","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"R48-20250627","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology solution set oversight committee.","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R49-20250627","doi-asserted-by":"crossref","first-page":"3059864","DOI":"10.1155\/2020\/3059864","article-title":"Decreased mortality with beta-blocker therapy in HFpEF patients associated with atrial fibrillation.","volume":"2020","author":"Yang","year":"2020","journal-title":"Cardiol Res Pract"},{"key":"R50-20250627","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","article-title":"Lenient versus strict rate control in patients with atrial fibrillation.","volume":"362","author":"Van Gelder","year":"2010","journal-title":"N Engl J Med"},{"key":"R51-20250627","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"R52-20250627","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1007\/s00380-021-01876-1","article-title":"Heart failure with mid-range ejection fraction and the effect of \u03b2-blockers after acute myocardial infarction.","volume":"36","author":"Song","year":"2021","journal-title":"Heart Vessels"},{"key":"R53-20250627","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"R54-20250627","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jchf.2017.10.014","article-title":"Relative impairments in hemodynamic exercise reserve parameters in heart failure with preserved ejection fraction: a study-level pooled analysis.","volume":"6","author":"Pandey","year":"2018","journal-title":"JACC Heart Fail"},{"key":"R55-20250627","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/jamacardio.2022.5320","article-title":"Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction: the myPACE randomized clinical trial.","volume":"8","author":"Infeld","year":"2023","journal-title":"JAMA Cardiol"},{"key":"R56-20250627","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13506129.2021.1981281","article-title":"Utilization and tolerance of beta-blockers among patients with AL amyloidosis.","volume":"29","author":"Briasoulis","year":"2022","journal-title":"Amyloid"},{"key":"R57-20250627","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/13506129.2024.2431082","article-title":"Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy.","volume":"32","author":"Cabrera-Romero","year":"2025","journal-title":"Amyloid"},{"key":"R58-20250627","first-page":"71","article-title":"Cardiac amyloidosis and its new clinical phenotype: heart failure with preserved ejection fraction.","volume":"109","author":"Mesquita","year":"2017","journal-title":"Arq Bras Cardiol"},{"key":"R59-20250627","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/clc.24058","article-title":"Association between the beta-blockers, calcium channel blockers, all-cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials.","volume":"46","author":"Wu","year":"2023","journal-title":"Clin Cardiol"},{"key":"R60-20250627","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/03009734.2018.1490831","article-title":"The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure.","volume":"124","author":"Savarese","year":"2019","journal-title":"Ups J Med Sci"},{"key":"R61-20250627","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cardfail.2023.08.008","article-title":"Does Heterogeneity Exist in Treatment Associations With Renin-Angiotensin-System Inhibitors or Beta-blockers According to Phenotype Clusters in Heart Failure with Preserved Ejection Fraction?","volume":"30","author":"Uijl","year":"2024","journal-title":"J Card Fail"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000987","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:00:50Z","timestamp":1751029250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":61,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000987","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}